Precipitating Pseudomonas aeruginosa antibodies and antimicrobial therapy in cystic fibrosis patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 4, 1996, Pages 309-312

  Trancassini, M ^a   De Vito, D ^a   Cimino, G ^a   Antonelli, M ^a   Quattrucci, S ^a   Cipriani, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIINFECTIVE AGENT; VIRULENCE FACTOR;

ADOLESCENT; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; ASPIRATION; BACTERIAL COLONIZATION; CHILD; CLINICAL ARTICLE; CROSSED IMMUNOELECTROPHORESIS; CYSTIC FIBROSIS; FEMALE; HUMAN; INFANT; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SAMPLE; SERUM; SPUTUM;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; ENTEROBACTERIACEAE; FEMALE; HUMANS; INFANT; MALE; PRECIPITINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; STAPHYLOCOCCUS AUREUS;

EID: 0029938848     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01695663     Document Type: Article

References (23)

1. Matthews LW, Drotar D: Cystic fibrosis - a challenging long-term chronic disease. Pediatric Clinics of North America 1984, 31: 133-152.
2. Bauernfeind A, Bertele RM, Harms K, Horl G, Jungwirth R, Petermuller C, Przylenk B, Weisslein-Pfister C: Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection 1987, 4: 270-277.
3. Woods DE, Sokol PA: Role of Pseudomonas aeruginosa extracellular enzymes in lung disease. Clinical and Investigative Medicine 1986, 9: 108-112.
4. Döring G: Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients. In: Campa M. (ed): Pseudomonas aeruginosa as an opportunistic pathogen. Plenum, New York, 1993, p. 245-273.
5. Høoiby N, Friss B, Jensen K, Koch C, Moller NE, Stovring S, Szaff M: Antimicrobial chemotherapy in cystic fibrosis patients. Acta Paediatrica Scandinavica Supplementum 1982, 301: 75-100.
6. May TB, Shinabarger D, Maharaj R, Kato J, Chu L, De-Vault JD, Roychoudhury S, Zielinski NA, Berry A, Rothmel RK, Misra TK, Chakrabarty AM: Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infection of cystic fibrosis patients. Clinical Microbiology Reviews 1991, 4: 191-206.
7. Pier GB: Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. Journal of Infectious Diseases 1986, 151: 575-580.
8. Vasil ML: Pseudomonas aeruginosa: biology, mechanism of virulence, and epidemiology. Journal of Pediatric Research 1986, 108: 800-805.
9. Anwar H, Strap JL, Chen K, Costerton JW: Dynamic interaction of biofilm of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin. Antimicrobial Agents and Chemotherapy 1992, 36: 1208-1214.
10. Dalhoff A, Döring C: Action of quinolones on gene expression and bacterial membranes. Antibiotics and Chemotherapy 1987, 39: 205-214.
11. Morris G, Brown MRW: Novel modes of action of aminoglycoside antibiotics against Pseudomonas aeruginosa. Lancet 1988, 18: 1359-1360.
12. Grimwood K, To M, Rabbin HR, Woods DE: Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations. Antimicrobial Agents and Chemotherapy 1989, 33: 41-47.
13. Warren RL, Baker NR, Johnson J. Stapleton MJ: Selective inhibition of the accumulation of extracellular proteases of Pseudomonas aeruginosa by gentamicin and tobramicin. Antimicrobial Agents and Chemotherapy 1985, 27: 468-472.
14. Høiby N: Pseudomonas aeruginosa infection in cystic fibrosis: diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathologica et Microbiologica Scandinavica 1977, Supplement 262: 7-71.
15. Welch DF, Muszynski MJ, Pai CH, Marcon MJ, Hirbar MM, Gilligan PH, Matsen JM, Ahlin PA, Hilman BC, Chartrand SA: Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis. Journal of Clinical Microbiology 1987, 25: 1730-1734.
16. Weeke B: Crossed immunoelectrophoresis. Scandinavian Journal of Immunology 1973, 2, Supplement 1: 47-56.
17. Høiby N: Cystic fibrosis infection. Schweizerische Medizinische Wochenschrift 1991, 121: 105-109.
18. Pedersen S, Espersen F, Høiby N: Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 1987, 25: 1830-1836.
19. Høiby N: Antibodies against Pseudomonas aeruginosa in serum from normal persons and patients colonized with mucoid or non-mucoid Pseudomonas aeruginosa: results obtained by crossed immunoelectrophoresis. Acta Pathologica et Microbiologica Scandinavica 1977, Section C, 85: 142-148.
20. Trancassini M, Brenciaglia MI, Ghezzi MC, Cipriani P, Filadoro F: Modification of Pseudomonas aeruginosa virulence factors by sub-inhibitory concentrations of antibiotics. Journal of Chemotherapy 1992, 4: 78-81.
21. Masuda N, Ohya S: Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1992, 36: 1847-1851.
22. Buscher KH, Cullmann W, Dick W, Opferkuch W: Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrobial Agents and Chemotherapy 1987, 31: 703-708.
23. Cipriani P, Giordano A, Magni A, Papa F, Filadoro F: OM alterations in Pseudomonas aeruginosa after five day exposure to quinolones and carbapenems. Drugs under Experimental and Clinical Research 1995, 21: 139-144.